homemarket Newsstocks News

Dr Reddy's shares plunge 8% on uncertainty over NuvaRing launch in US

Dr Reddy's shares plunge 8% on uncertainty over NuvaRing launch in US

Dr Reddy's shares plunge 8% on uncertainty over NuvaRing launch in US
Profile image

By CNBC-TV18 Aug 14, 2019 10:07:36 AM IST (Published)

Shares of Dr. Reddy's Laboratories plunged 8 percent on Wednesday after the company received a Complete Response Letter from the US Food and Drug Administration (USFDA) for its version of NuvaRing.

Shares of Dr Reddy's Laboratories plunged as much as 8 percent to Rs 2,352 on Wednesday amid concerns the drugmaker’s plan to launch a generic version of a female contraceptive in the US may face a delay.

Recommended Articles

View All

The company said it has received a complete response letter from the US Food and Drug Administration (USFDA) for its version of NuvaRing— a small, flexible vaginal ring used to prevent pregnancy.  While Dr Reddy's said it is preparing a response to the drug regulator’s letter, it did not give much clarity on how much time it would take.
According to brokerage Citi, Nuvaring launch is unlikely to happen before mid CY20 and further delay can’t be ruled out. Citi has cut  Dr Reddy's FY20 EPS estimates by 8 percent. It maintained 'sell' rating on the stock but cut the price target to Rs 2,375 per share from Rs 2,540 earlier.
Mirroring the concerns, the stock was trading 6 percent lower at Rs 2,405.55 at 9:45 AM on the Bombay Stock Exchange. In comparison, the benchmark Sensex index was down 0.3 percent at 37,058.
In the quarter ended June 30, Dr Reddy's Laboratories reported a 45 percent (YoY) rise in its net profit at Rs 662.8 crore led by a one-time gain. Revenues grew 3 percent YoY at Rs 3,843.4 crore.
 
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng